- Home
- DPRO vs TLSI Comparison
DPRO vs TLSI Comparison
Compare DPRO & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DPRO | TLSI |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | Canada | United States |
| Employees | N/A | 110 |
| Industry | Aerospace | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.7M | 267.1M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | DPRO | TLSI |
|---|---|---|
| Price | $6.64 | $3.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $15.67 | $7.00 |
| AVG Volume (30 Days) | ★ 1.9M | 209.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.16 | $41.93 |
| Revenue Next Year | $145.52 | $41.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.63 | $3.42 |
| 52 Week High | $14.37 | $7.95 |
Technical Indicators
Market Signals| Indicator | DPRO | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 30.89 |
| Support Level | $6.23 | $3.79 |
| Resistance Level | $7.15 | $5.51 |
| Average True Range (ATR) | 0.50 | 0.31 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 40.92 | 1.32 |
Price Performance
Historical ComparisonAbout DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.